In agreement with these observations, in our study, the levels of ESR, CRP and RF in patients treated with Group-II were lower than those treated with Group-I (P<0.05), suggesting that the combination of disease modifying anti-rheumatic drugs and glucocorticoids in the treatment of patients with rheumatoid arthritis is helpful to further improve the serological indexes of patients. Here, ESR1 is linked to rheumatoid arthritis.